Hepcidin as a Predictor for the IVI Mediated Increase in Haemoglobin Levels — PREDICT-IVI  

Anemia Clinical Trial

Official title: Hepcidin as a Predictor for the IVI Mediated Increase in Haemoglobin Levels Prior to Elective Surgery

Status Recruiting

Clinical Trial Summary

The study is a multidisciplinary study, which involves all kind of medical specialties. Patients, who are scheduled for elective surgery, will be seen at a multidisciplinary anaesthesia/Patient Blood Management (PBM) clinic and screened for anaemia prior to surgery. Anaemic patients will eventually be treated with 500mg of iron isomaltoside.

Clinical Trial Description

Hgb levels, standard iron parameters and hepcidin will be assessed. Additional parameters that might influence Hgb or IVI levels will be documented. All main analyses will be pre-defined in detail in a statistical analysis plan. In order to analyse the responsiveness to IVI, the change in Hgb levels from PBM clinic to day 0 will be analysed using multivariable regression models. The association of change in Hgb and hepcidin will be analysed adjusting for potentially confounding factors as age, gender or number of days from PBM clinic to surgery. The correlation of hepcidin and standard iron parameters will be assessed. Based on the increase in Hgb levels, responders to IVI will be defined. The definition of good- bad responder in terms of delta Hgb levels depends on the time between IVI substitution and surgery. ROC analyses will be performed and potential predictors (e.g. hepcidin, ferritin) will be compared concerning the area under the ROC curve (AUC). ;

Related Conditions & MeSH terms

• Anemia
• IV Iron

• NCT number: NCT04263571
• Study type: Observational
• Source: Goethe University
• Contact: Andrea U Steinbicker, Prof Dr MPH
• Phone: +49 69630186188
• Email: andrea.steinbicker@kgu.de
• Status: Recruiting
• Start date: April 12, 2019
• Completion date: December 31, 2023